Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Munn

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
Current Opinion in Immunology|February 8, 2006
Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulationDavid H Munn
Annals of the New York Academy of Sciences|June 26, 2002
Tolerogenic antigen-presenting cellsDavid H Munn
Frontiers in Bioscience (Elite Edition)|December 29, 2011
Blocking IDO activity to enhance anti-tumor immunityDavid H Munn
Blood|August 8, 2009
Th17 cells in ovarian cancerDavid H Munn
The Journal of Clinical Investigation|January 17, 2018
The host protecting the tumor from the host - targeting PD‑L1 expressed by host cellsDavid H Munn
European Journal of Immunology|January 28, 2010
Lineage-specific transcription factors in unexpected placesDavid H Munn
Current Opinion in Immunology|November 27, 2015
Immune suppressive mechanisms in the tumor microenvironmentDavid H Munn, Vincenzo Bronte
Nature Reviews. Immunology|December 8, 2007
Creating immune privilege: active local suppression that benefits friends, but protects foesAndrew L Mellor, David H Munn
Trends in Immunology|February 4, 2016
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and ToleranceDavid H Munn, Andrew L Mellor
Immunological Investigations|September 29, 2012
Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor toleranceTheodore S Johnson, David H Munn
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Current Opinion in Immunology|February 8, 2006
Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulationDavid H Munn
Annals of the New York Academy of Sciences|June 26, 2002
Tolerogenic antigen-presenting cellsDavid H Munn
Frontiers in Bioscience (Elite Edition)|December 29, 2011
Blocking IDO activity to enhance anti-tumor immunityDavid H Munn
Blood|August 8, 2009
Th17 cells in ovarian cancerDavid H Munn
The Journal of Clinical Investigation|January 17, 2018
The host protecting the tumor from the host - targeting PD‑L1 expressed by host cellsDavid H Munn
European Journal of Immunology|January 28, 2010
Lineage-specific transcription factors in unexpected placesDavid H Munn
Current Opinion in Immunology|November 27, 2015
Immune suppressive mechanisms in the tumor microenvironmentDavid H Munn, Vincenzo Bronte
Nature Reviews. Immunology|December 8, 2007
Creating immune privilege: active local suppression that benefits friends, but protects foesAndrew L Mellor, David H Munn
Trends in Immunology|February 4, 2016
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and ToleranceDavid H Munn, Andrew L Mellor
Immunological Investigations|September 29, 2012
Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor toleranceTheodore S Johnson, David H Munn
Pageof 15